The Mounjaro starting dose isn't the dose that does the work

The myth: 2.5mg is a weak dose you should push past as fast as possible

This is one of the most common misunderstandings our prescribers encounter. People arrive expecting 2.5mg to be a formality, something to get through quickly on the way to the 'real' dose. In practice, the starting dose exists for a clear clinical reason: tirzepatide slows the movement of food through the stomach and changes appetite signals quite sharply, and the gastrointestinal side effects (nausea, loose stools, indigestion) are most pronounced when the medicine is new to your system. Starting low reduces the chance that side effects become severe enough to stop treatment altogether.

The NHS medicines page for tirzepatide is clear that 2.5mg is the standard starting point under the licensed schedule, with titration every four weeks as tolerated. Rushing that schedule doesn't improve outcomes, it tends to worsen tolerability. Some people stay at a given step for longer than four weeks if their prescriber judges it appropriate. The goal is the highest dose you tolerate well, which varies considerably between individuals.

There is also no ceiling you are expected to reach. Not everyone ends treatment at 15mg; some people maintain excellent results at 7.5mg or 10mg. The prescriber reviews the picture at each repeat, weight trend, side effects, any new health information. That review is the mechanism, not a box-tick.

What the titration schedule actually looks like

UK Mounjaro comes in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Each KwikPen contains four weekly doses. The licensed schedule, as set out in the Summary of Product Characteristics on the electronic Medicines Compendium, moves through those steps in approximately four-week intervals, though 'approximately' is doing real work there. A prescriber may slow progression if tolerability is an issue, or review whether a dose increase is warranted before a patient orders the next pen.

The question of what counts as a good starting point for tirzepatide is partly answered by the licence and partly by individual health history. Someone transferring from another GLP-1 medicine may not start at 2.5mg; someone with a history of GI sensitivity may benefit from a slower ramp. These are clinical judgements. The SmPC sets the floor; the prescriber reads the patient.

For context on how the first pen period tends to feel in practice, the 2.5mg starting period guidance covers what to expect week by week. The short version: most early side effects settle within the first two weeks. Staying hydrated and eating smaller, lower-fat meals during that window helps considerably. Protein intake matters more as appetite drops later in the schedule.

Why the starting dose still matters for long-term results

It would be easy to dismiss the 2.5mg phase as dead time. It isn't. Tolerability in the early weeks predicts adherence across the whole treatment course, and adherence is one of the strongest predictors of outcome. In the SURMOUNT-1 trial, involving over 2,500 adults with obesity, those who reached and maintained the 15mg dose achieved average body-weight reductions of around 20–21% over 72 weeks. That outcome depends on people staying on treatment long enough to get there.

There is also a metabolic adjustment happening. Appetite suppression, changes in food preferences, and shifts in hunger timing all begin at 2.5mg, you may notice them before you notice the number on the scale moving. Some people find the first few weeks surprisingly manageable; others find them tough. Both are normal. Neither is a signal that the medicine is or isn't working.

For a broader sense of how Mounjaro fits into longer-term weight management, including what happens at maintenance, that page covers the evidence. And if cost across the dose schedule is on your mind, the Mounjaro cost page explains how pricing relates to dose in the private market.

How a prescriber decides when to increase your dose

At each clinical review (and at nume every repeat order is reviewed by a GPhC-registered prescriber before it is approved) the prescriber considers a few things. Has weight loss continued? Are side effects manageable? Has anything changed in your health history? Evidence of progress and tolerability both factor in. A dose increase is not automatic just because four weeks have passed.

If you have been at 5mg and wondering what the differences are in practice, the 5mg Mounjaro page covers the evidence at that step. For those deciding between starting points, starting Mounjaro specifically for weight loss walks through the clinical criteria in more detail. And if the difference between licensed private eligibility and NHS access criteria is something you want to understand before booking a consultation, the treatment overview lays that out plainly.

A consultation with our clinical team is the right place to ask which step you are likely to start at, given your health history. A real clinician reads your answers the same day, if you order before noon on a working day, dispatch follows the same afternoon once you're approved. Check your eligibility by starting a free consultation.